ライフサイエンスコーパス: rational drug design

1 euronal proteins that could be exploited for rational drug design.

2 the wealth of information being generated in rational drug design.

3 cross-talk provide valuable insight towards rational drug design.

4 on in real time, can be effectively used for rational drug design.

5 -cycle and presents an attractive target for rational drug design.

6 the interaction provide a starting point for rational drug design.

7 remains an important outstanding problem in rational drug design.

8 he innovative use of new screening tools and rational drug design.

9 xcellent example of progress in the field of rational drug design.

10 t also the identification of new targets for rational drug design.

11 ids by small molecules which is the basis of rational drug design.

12 ed by the lack of structural information for rational drug design.

13 provide insight into novel methodologies for rational drug design.

14 e without access to the traditional tools of rational drug design.

15 VAN and AR as well as attractive targets for rational drug design.

16 studies of structure-function relations and rational drug design.

17 hat modulate behavior, providing targets for rational drug design.

18 ntial of the method in aiding the process of rational drug design.

19 ivity, thus providing a template for further rational drug design.

20 the urgent need for new methods that enable rational drug design.

21 te that could be exploited in the process of rational drug design.

22 dual waters and how they may be exploited in rational drug design.

23 ng to receptors provides insights useful for rational drug design.

24 f protein structures of suitable quality for rational drug design.

25 and inhibitor sensitivity, which may inform rational drug design.

26 ich serves as a promising starting point for rational drug design.

27 APP amyloid inhibitors, and this has limited rational drug design.

28 pocket residues, which could be critical for rational drug design.

29 halogen bonds for molecular recognition and rational drug design.

30 tivity of bexarotene can be achieved through rational drug design.

31 ities for diagnosis, drug repositioning, and rational drug design.

32 ts and should be taken into consideration in rational drug design.

33 ding networks that can greatly contribute to rational drug design.

34 vity, sequence-specific HSP recognition, and rational drug design.

35 d lyase catalytic capabilities and assist in rational drug design.

36 n structures provide a valuable resource for rational drug design.

37 holesterol assisted by tools associated with rational drug design.

38 nnel open, a question that is fundamental to rational drug design.

39 a surface cavity identified as a target for rational drug design.

40 interference, represents a new paradigm for rational drug design.

41 w structural and functional data will inform rational drug design.

42 d drug modulation of alpha7, key pillars for rational drug design.

43 simulated and observed structures should aid rational drug design.

44 receptor signaling states and for initiating rational drug design.

45 loop receptors to facilitate structure-based rational drug design.

46 These findings offer a foundation for rational drug design.

47 binding site with important consequences for rational drug design.

48 ing residues in p66 as a possible target for rational drug design.

49 ntermediates may offer new opportunities for rational drug design.

50 itions is a prerequisite for structure-based rational drug design.

51 of melanoma cells that can be exploited for rational drug design.

52 on contributes to leukemia, is important for rational drug design.

53 ecular species of a ligand and in associated rational drug design.

54 By use of rational drug design, a targeted covalent inhibitor 3 (C

55 peractive mutant could serve as a target for rational drug design aimed at repressing SloR-mediated v

56 of the biochemistry of trypanosomatids make rational drug design an attractive approach, but targets

57 e been identified by serendipity rather than rational drug design and are not ideal because of limite

58 ncluding rationale and lessons to learn; (4) rational drug design and development; and (5) consensus

59 al, represents a promising lead compound for rational drug design and discovery.

60 click-chemistry products may prove useful in rational drug design and drug optimization.

61 entary molecular tool to hydrogen bonding in rational drug design and in material sciences.

62 proteins is pivotal to achieving success in rational drug design and in other biotechnological endea

63 ystal structures sets serious limitations to rational drug design and in silico searches for subtype-

64 Pharmacophores are widely used for rational drug design and include those based on receptor

65 se the available starting scaffolds for both rational drug design and library selection methods.

66 r current work highlights the further use of rational drug design and molecular modeling to produce a

67 positional candidates, and the prospects for rational drug design and personalized medicine.

68 vide a foundation for applications including rational drug design and protein engineering.

69 Our results indicate that integrating rational drug design and supramolecular nanochemistry ca

70 invasion by the malaria parasite and aid in rational drug design and vaccines.

71 Molecular recognition is the basis of rational drug design, and for this reason it has been ex

72 creening and computer-aided, structure-based rational drug design, and identify a lead compound, SP-1

73 modification and will aid a structure-guided rational drug design approach to treating multidrug-resi

74 soxazole-based anti-TB compounds by applying rational drug design approach.

75 hallenge for assessing their utility is that rational drug design approaches require foreknowledge of

76 of novel inhibitors through structure-aided rational drug design approaches.

77 Implications for in particular, rational drug design, are discussed.

78 high-affinity site opens the possibility for rational drug design based on linking and modifying it a

79 sma gondii represents a promising target for rational drug design, because it can create intracellula

80 High-resolution structures are essential for rational drug design, but only a few are available due t

81 drug design, a terminology used to describe rational drug design by complementing the structure, spa

82 eloped two novel templates, 3 and 4, through rational drug design by identifying the key pharmacophor

83 These results have implications in rational drug design by specifically targeting the aroma

84 Our experimental approach suggests that rational drug design can develop new rexinoids with impr

85 These results demonstrate how rational drug design can improve in vivo specificity, wi

86 The de novo approach to structure-based rational drug design can provide a powerful tool for sug

87 Using rational drug design coupled with traditional screening

88 sented here, it will be possible to initiate rational drug design efforts around this natural product

89 d reverse genetics methods paves the way for rational drug design efforts to inhibit viral RNA synthe

90 nderstanding this pathway fully will lead to rational drug design for allergic disease.

91 This could open a new direction into rational drug design for amyloidogenic proteins.

92 Our results indicate that rational drug design for GPCR targets is a feasible appr

93 oinsufficiency in humans will be amenable to rational drug design for improved seizure control and co

94 ptide in a serpin and provides the basis for rational drug design for mimetics that will prevent poly

95 hat MAD-28 can now be used as a template for rational drug design for NEET Fe-S cluster-destabilizing

96 Our work has implications for rational drug design for nicotinic receptors and sheds l

97 isozymes and serves as an initial step in a rational drug design for NOS.

98 ing as direct therapeutics and as a tool for rational drug design for Parkinson's disease.

99 nd ALK kinase domains will facilitate future rational drug design for ROS1- and ALK-driven NSCLC and

100 ntly revealed common features that may allow rational drug design for therapeutic intervention.

101 discussed is application of the algorithm to rational drug design from a new development platform.

102 ment of nonpeptide fusion inhibitors through rational drug design has been hampered by the limited ac

103 Unfortunately, the use of computational rational drug design has been limited by the challenges

104 Rational drug design has reduced morbidity and mortality

105 some of the CYP51 key features important for rational drug design have remained obscure.

106 the GM-CSF signaling pathway as a target for rational drug design in JMML.

107 phasis on providing a possible framework for rational drug design in order to develop future isoform-

108 alpha1-antitrypsin as a potential target for rational drug design in order to prevent polymer formati

109 The first agent to emerge from such a rational drug design is azatoxin, a hybrid drug that fus

110 A unifying principle of rational drug design is the use of either shape similari

111 In conclusion, rational drug design led to a compound combining improve

112 tability, but additionally opens avenues for rational drug design, mimicking the compensatory mutatio

113 Modern rational drug design not only deals with the search for

114 no Sec7 domain interaction and may guide the rational drug design of competitive inhibitors of Arno e

115 s study provides precise information for the rational drug design of small molecule inhibitors for th

116 These structures provide a foundation for rational drug design of small molecule inhibitors to be

117 ith continuing advances in biotechnology and rational drug design, offer substantial hope for the con

118 creening of our in-house library followed by rational drug design, organic synthesis, and biological

119 strategy, which reverses the target --> lead rational drug design paradigm.

120 ape of oligomerization may provide hints for rational drug design, preventing amyloid-associated dise

121 urther optimization as part of the iterative rational drug design process.

122 Structural studies are part of a rational drug design program aimed at inhibiting the S10

123 te, which assists in functional analysis and rational drug-design programmes.

124 are relevant in vivo would be valuable in a rational drug design project.

125 at alchemical free energy methods can assist rational drug design projects.

126 hould help focus structure-function studies, rational drug design, protein engineering, and functiona

127 for mutagenesis experiments and, thus, focus rational drug design, protein engineering, and functiona

128 ffinity of a lead molecule in the context of rational drug design remains uncertain.

129 bility of novel therapeutics, it complicates rational drug design, since the in vivo response to a bi

130 portance for studies of enzymatic reactions, rational drug design, small-molecule binding to proteins

131 luable insight into PKC specificity and into rational drug design strategies for PKC selective leads.

132 o become templates for the creation, through rational drug design strategies, of pharmaceuticals high

133 ygenated lipids, and PAF remain the focus of rational drug design targets given their established rol

134 Rational drug design that optimizes preferential effecto

135 ture is a problem of paramount importance in rational drug design (the "docking" problem).

136 However, to efficiently guide rational drug design, the binding site of BQCA needs to

137 XPRTase), and could provide a good model for rational drug design through specific enzyme inhibition.

138 ncorporation and can provide information for rational drug design to help combat ASFV in the future.

139 on inside the cell and therefore incorporate rational drug design to impact antibiotic uptake.

140 Together, these insights provide avenues for rational drug design to modulate the activities of these

141 tion mutagenesis, chemical modification, and rational drug design to obtain higher potency and select

142 drug residence time should be emphasized in rational drug design to overcome the kinase resistance.

143 This pocket may provide a target for rational drug design to prevent the formation of polymer

144 enic polypeptides, providing information for rational drug design to treat IAPP induced beta-cell dea

145 Rational drug design, to affect complex processes such a

146 A recent trend toward more rational drug design was observed.

147 These structures provide a foundation for rational-drug design, which may lead to the development

148 These results provide exciting new ideas for rational drug design with RNA as is now common with DNA